| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -55,348 | - |
| Depreciation | 313 | 223 |
| Amortization of intangible assets | 499 | 333 |
| Stock-based compensation | 16,487 | 10,870 |
| Non-cash lease expense | 847 | - |
| Accounts receivable | 15 | - |
| Inventory | 57 | - |
| Prepaid expenses and other current assets | 538 | - |
| Other receivables | 14 | - |
| Other long-term assets | 28 | - |
| Accounts payable | 1,318 | - |
| Accrued expenses | -1,823 | - |
| Lease liabilities | -1,008 | - |
| Net cash used in operating activities | -39,367 | -26,328 |
| Purchases of property and equipment | 210 | 148 |
| Purchases of intangible assets | 20 | 20 |
| Net cash used in investing activities | -230 | -168 |
| Proceeds from issuance of common stock under employee stock purchase plan | 593 | 352 |
| Proceeds from issuance of common stock and warrants in relation to rights offering, net of issuance costs | 0 | - |
| Proceeds from exercises of warrants, net of issuance costs | 14,080 | 14,063 |
| Proceeds from exercises of stock options | 2,100 | 392 |
| Issuance costs in relation to at-the-market equity offering | 0 | 0 |
| Net cash provided by financing activities | 16,773 | 14,807 |
| Net (decrease) increase in cash and cash equivalents | -22,824 | -11,689 |
| Cash and cash equivalents at beginning of period | 118,038 | - |
| Cash and cash equivalents at end of period | 95,214 | - |
PULSE BIOSCIENCES, INC. (PLSE)
PULSE BIOSCIENCES, INC. (PLSE)